Peregrine Pharmaceuticals Doses First Patient In Phase II Trial Of Bavituximab In Pat

[News]

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer.

More... (http://www.medicalnewstoday.com/articles/117911.php)